Boston Scientific Corporation provided earnings guidance for the full year of fiscal 2018 and 2019. For 2019, the company announced guidance will deliver double-digit EPS growth despite, the company thinks, about a 4% to 5% headwind in 2018 and about a $0.02, $0.03 dilution impact. The company expects to deliver double-digit EPS growth in 2018 despite significant investments in the company to provide long-term growth.